Search: “”

Artificial intelligence (AI) will shape our world in the coming years. People already speculate how AI can superhumanly solve any human problem. What will its role be in healthcare?

Developing of novel drugs is always a high-risk endeavor and success should result in a financial reward. However, what is an acceptable cost for the treatment of severe rare disorders?

Our vision at Herantis is to produce innovative therapeutics for patients. Based on leading academic research, our novel drug candidates are currently in clinical trials for the treatment of Parkinson’s disease and secondary lymphedema. You can find more detailed information on the studies as well as further resources below. Looking for more information? Please contact us at: info (at) herantis.com

Herantis Pharma is a publicly listed (HRTIS) drug development company aiming to revolutionize the treatment of diseases with unmet clinical needs. Based on leading academic research published in high-impact journals including Nature and Science, the two ongoing clinical development programs explore the potential of our novel drug candidates in Parkinson’s disease and secondary lymphedema. For Parkinson’s disease, our neuroprotective and neurorestorative drug candidate CDNF is intended to become the first disease-modifying treatment with further potential in other neurodegenerative diseases. Our Lymfactin® gene therapy is targeted as the first curative drug for the treatment of cancer associated secondary lymphedema. Both Parkinson’s disease and lymphedema remain conditions in which current treatments only address symptoms and therefore do not enable long-term improvement for patients. To successfully move forward our vision of breaking the boundaries of standard therapeutic approaches, Herantis has assembled a group of highly experienced professionals for the team, Board of Directors and Scientific Advisory Board. Sign up for our bi-monthly newsletter

Herantis Pharma was created by a merger of two pharmaceutical companies, Hermo Pharma and Laurantis Pharma.

Use of this website and applicable law These terms and conditions (hereinafter the “Terms and Conditions”) are applied to the use of Herantis Pharma Plc’s (hereinafter “Herantis”) website. By accessing Herantis’ website you agree to these Terms and Conditions. These Terms and Conditions, the use of Herantis’ website and the content therein are governed by the Laws of Finland, excluding any rules for choice of law. Any dispute, claim, or matter arising under or in connection with these Terms and Conditions, the use of Herantis’ website or the content therein, shall be resolved in the public courts, whereby the District Court of Helsinki acts as the court of first instance. Copyrights Herantis’ website and the content therein are the property and subject to the copyright of Herantis. Herantis reserves all rights not expressly granted herein to Herantis’ website and the contents therein. Reproduction and copying, amending, saving and storing, distributing or similar use of part or all of this website content in any form without the express prior written permission of Herantis is prohibited, unless otherwise expressly stated in these Terms and Conditions. Browsing Herantis’ website or printing copies of or extracts from Herantis’ website is allowed for your personal, non-commercial use only. Use of and referral to press releases, blogs, and other material in Herantis’ website that is to be commonly and clearly understood as public is permitted in public communication in the condition that Herantis’ website as the source of such information is stated in such communication. Disclaimers This website and the contents herein are provided “as is” and solely as a general presentation of Herantis. Herantis does not warrant that the information on this website is up-to-date or timely, or that this website is available uninterruptedly, or without errors. Herantis reserves the right to alter, amend, modify, and revise this website and the contents therein, and to deny or restrict access to this website at any time in the discretion of Herantis without a notification made to you. NO WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF TITLE, FITNESS FOR A PARTICULAR PURPOSE, OR THE AVAILABILITY, RELIABILITY, ACCURACY, CONTENT OR ANY OTHER MATTER IS MADE BY HERANTIS REGARDING THIS WEBSITE OR THE MATERIAL THEREIN. HERANTIS IS NOT LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR SPECIAL LOSS OR DAMAGE ARISING DIRECTLY OR INDIRECTLY OUT OF THE USE OF OR INABILITY TO USE THIS WEBSITE. This website or the material therein does not contain, and it should not be interpreted as containing, a request, recommendation, or advice to invest in shares or other securities issued by Herantis. The information contained in this website is not and it should not be interpreted as an offer to sell or purchase securities in any country, including the United States of America, Australia, Canada, Hong Kong, Japan, Singapore, or South Africa. Projections, forecasts, opinions, and expectations regarding a future event presented in this website shall not necessarily materialize. Earlier price development of shares or other securities should not be used as a guidance for future price development of a share or a security. Medical Information HERANTIS’ WEBSITE MAY CONTAIN GENERAL INFORMATION REGARDING DISEASES, MALADIES, ILLNESES OR OTHER MEDICAL CONDITIONS AND THEIR TREATMENT. SUCH INFORMATION IS PROVIDED FOR INFORMATIONAL AND BACKGROUND PURPOSES ONLY AND IT IS NOT MEANT TO BE NOR SHOULD IT BE APPLIED IN PATIENT CARE OR OTHER MEDICAL PURPOSES. INFORMATION PROVIDED ON HERANTIS’ WEBSITE DOES NOT SUBSTITUTE ADVICE PROVIDED BY A QUALIFIED HEALTH CARE PROFESSIONAL. YOU SHOULD ALWAYS CONSULT YOUR OWN DOCTOR OR OTHER HEALTH CARE PROFESSIONAL FOR ACCURATE MEDICAL ADVICE AND INFORMATION REGARDING DIAGNOSIS AND TREATMENT OF MEDICAL CONDITIONS. Links For your convenience, Herantis’ website may include links to third-party websites on the Internet. Herantis does not exercise control over the content of third-party websites and cannot and does not assume any responsibility for such websites or any content published therein. You should review and agree or reject any potential terms and conditions of such third-party sites independently. Further, you agree that Herantis does not recommend or endorse the content or potential products or services or any other information, recommendations or similar material that might be referred to or offered on such third-party website. Submitted material By sending or otherwise submitting files or other material to Herantis’ server, website or similar location, you agree that: (a) the material does not contain anything that might be deemed unlawful or otherwise unfit for use and publication; (b) the material does not contain viruses or similar harmful software; (c) you are the rightful owner of such material and provide such material to Herantis free of charge; (d) Herantis has a right to publish, copy, reproduce, modify and to otherwise use (including use for commercial purposes) such material free of charge and without any accountability or liability towards you; (e) you will not take any action or claim against Herantis in relation to material that you submit; and (f) you will hold Herantis harmless against any action or claim taken against Herantis by third parties in relation to material submitted by you and indemnify Herantis all direct and indirect damages caused by such third-party action or claim. Ownership The name “HERANTIS” and all rights related thereto are the exclusive property of Herantis. Brands, patterns, signs, names and similar content that appear on Herantis’ website may be protected and owned by Herantis or third parties. Your access to Herantis’ website shall not construe a permit to copy, license, use or in other manners to exploit such brands, patterns, signs, names and similar content. The service provider of this website is Herantis Pharma Plc, a public limited liability company having its registered address in Finland at Bertel Jungin Aukio 1, 02600 Espoo with the corporate identification number 2198665-7 (VAT number FI21986657).

The global direct healthcare costs are approaching $10 trillion. What does that signify? The CEO gives a concrete example to elucidate the potential significance of our work.